Aug. 10 at 4:13 PM
$MAIA Three deep dive models reviewed today's financials and indicate plenty of cash till mid to late 2027 well beyond Phase 3 intermim data. I realize this is AI but all three resulted in similar results with each satisfying my expectations.
Cash position is adequate to reach key clinical milestones, including potential completion of Phase 2 interim/efficacy data and into the expected Phase 3 interim analysis window in 2027, without needing immediate new cash.
Key financials (Q2 2026 10-Q, ended June 30, 2026)
Cash:
$27.6 million (vs.
$8.7 million at year-end 2025), boosted by the ~
$33 million gross (~
$31 million net) March 2026 equity offering.
Working capital: ~
$22.0 million; current liabilities ~
$6.3 million; no debt.
Net loss: Q2 ~
$7.9 million; H1 ~
$14.3 million.
Operating expenses: Q2 ~
$8.3 million (R&D ~
$5.6 million driven by trial expansion); H1 ~
$15.3 million.
Operating cash burn (H1 2026): ~
$12.1 million (~
$2.0 million/month average). Q2 burn ran higher than Q1 as clinical activity increased.
At the recent ~
$24 million annualized operating cash burn rate, the
$27.6 million cash supports roughly 12–14+ months of runway from June 30, 2026 (into roughly Q3–Q4 2027). If burn accelerates further with enrollment, it could compress toward ~12 months; modest interest/grant income provides a small offset. The company states the March proceeds are expected to fully fund the ongoing pivotal Phase 3 and that additional capital will ultimately be needed for operations and commercialization.
